Fatty Liver
Metabolic
Prevalence
25000.0 / 100K
Incidence
2000.0 / 100K/yr
8 drugs in development·7 companies·0 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| tvb-2640 | Sagimet Biosciences Inc. (SGMT) |
Phase 1(1)
| Drug | Company |
|---|---|
| nnc4005-001 | Novo Nordisk A/S (NVO) |
Preclinical(3)
Unknown(1)
| Drug | Company |
|---|---|
| legalon | Mylan II B.V. (MYL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Fatty Liver?
BioSniper tracks 8 drugs in development for Fatty Liver across 7 companies.
What is the prevalence of Fatty Liver?
The estimated prevalence of Fatty Liver is approximately 25000.0 per 100,000 population.
Deep-dive into Fatty Liver
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis